Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 52

Related Articles by Review for PubMed (Select 18266236)

1.

Increased dosing requirements for 6-mercaptopurine and azathioprine in inflammatory bowel disease patients six years and younger.

Grossman AB, Noble AJ, Mamula P, Baldassano RN.

Inflamm Bowel Dis. 2008 Jun;14(6):750-5. doi: 10.1002/ibd.20387.

PMID:
18266236
2.

Azathioprine: an update on clinical efficacy and safety in inflammatory bowel disease.

Lamers CB, Griffioen G, van Hogezand RA, Veenendaal RA.

Scand J Gastroenterol Suppl. 1999;230:111-5. Review.

PMID:
10499471
3.

Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review.

Gisbert JP, Gomollón F.

Am J Gastroenterol. 2008 Jul;103(7):1783-800. doi: 10.1111/j.1572-0241.2008.01848.x. Epub 2008 Jun 28. Review.

PMID:
18557712
4.

Azathioprine: state of the art in inflammatory bowel disease.

Sandborn WJ.

Scand J Gastroenterol Suppl. 1998;225:92-9. Review.

PMID:
9515759
5.

Optimizing immunomodulator therapy for inflammatory bowel disease.

Dubinsky MC.

Curr Gastroenterol Rep. 2003 Dec;5(6):506-11. Review.

PMID:
14602061
6.

Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine.

Nielsen OH, Vainer B, Rask-Madsen J.

Aliment Pharmacol Ther. 2001 Nov;15(11):1699-708. Review.

7.

Immunosuppressive drugs in the treatment of inflammatory bowel disease.

Aranda R, Horgan K.

Semin Gastrointest Dis. 1998 Jan;9(1):2-9. Review.

PMID:
9547850
8.

Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review.

Gisbert JP, González-Lama Y, Maté J.

Am J Gastroenterol. 2007 Jul;102(7):1518-27. Epub 2007 Mar 27. Review.

PMID:
17391318
9.

Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine.

Su C, Lichtenstein GR.

Gastroenterol Clin North Am. 2004 Jun;33(2):209-34, viii. Review.

PMID:
15177535
10.

Severe pulmonary toxicity after azathioprine/6-mercaptopurine initiation for the treatment of inflammatory bowel disease.

Ananthakrishnan AN, Attila T, Otterson MF, Lipchik RJ, Massey BT, Komorowski RA, Binion DG.

J Clin Gastroenterol. 2007 Aug;41(7):682-8. Review.

PMID:
17667053
11.

Refractory IBD: medical management.

Tremaine WJ.

Neth J Med. 1997 Feb;50(2):S12-4. Review.

PMID:
9050327
12.

Azathioprine or 6-mercaptopurine for inflammatory bowel disease: do risks outweigh benefits?

Su CG, Stein RB, Lewis JD, Lichtenstein GR.

Dig Liver Dis. 2000 Aug-Sep;32(6):518-31. Review.

PMID:
11057928
13.

Thiopurine hepatotoxicity in inflammatory bowel disease: the role for adding allopurinol.

Leong RW, Gearry RB, Sparrow MP.

Expert Opin Drug Saf. 2008 Sep;7(5):607-16. doi: 10.1517/14740338.7.5.607 . Review.

PMID:
18759713
15.

Thiopurine therapy: when to start and when to stop.

McGovern DP, Travis SP.

Eur J Gastroenterol Hepatol. 2003 Mar;15(3):219-23. Review.

PMID:
12610314
16.

Immunosuppressant therapy of inflammatory bowel disease. Pharmacologic and clinical aspects.

Goldstein F.

J Clin Gastroenterol. 1987 Dec;9(6):654-8. Review.

PMID:
3327885
17.

Review article: Reproduction in the patient with inflammatory bowel disease.

Heetun ZS, Byrnes C, Neary P, O'Morain C.

Aliment Pharmacol Ther. 2007 Aug 15;26(4):513-33. Review.

18.

[Azathioprine treatment of Crohn disease].

Thomsen MK, Vilien M, Gerner CU.

Ugeskr Laeger. 2000 Jan 17;162(3):323-6. Review. Danish.

PMID:
10680466
19.

[Monitoring of thiopurine methyltransferase and thiopurine metabolites to optimize azathioprine therapy in inflammatory bowel disease].

Gisbert JP, González-Lama Y, Maté J.

Gastroenterol Hepatol. 2006 Nov;29(9):568-83. Review. Spanish.

PMID:
17129552
20.

Azathioprine in inflammatory bowel disease, a safe alternative?

Tanis AA.

Mediators Inflamm. 1998;7(3):141-4. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk